Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $144.76M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.24M
Average 0.28M
Returns on capital
Sutro Biopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
144.3%
avg -61.1%
ROIC
-98.5%
avg -43.9%
ROA
-109.9%
avg -35.7%
Analysis
ROE is currently the strongest return metric at 144.3% versus its period average of -61.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jane Chung | Chief Executive Officer & Director | USD 1.16M | 55 | 0 | <0.01% |
Hans-Peter Gerber | Chief Scientific Officer | USD 771.35K | 62 | 3.75K | 0.04% |
Gregory K. Chow | Chief Financial Officer | USD 520.58K | 53 | 4.72K | 0.05% |
David Pauling | Chief Administrative Officer & General Counsel | — | 52 | 0 | <0.01% |
Jonathan Fawcett DPHIL MBBS | VP & Head of Clinical Development | — | — | — | — |
Lucas Donigian | Senior Vice President of Business Development | — | — | — | — |
Regina Cheng | Vice President & Controller | — | — | — | — |
James R. Swartz | Founder | — | — | — | — |
Kari E. Leetch | Senior VP and Head of People & Culture | — | — | — | — |
Devendra Luhar | Senior Vice President of Technical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +14.8% | -5.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.8% over three years. Forward estimates point to Revenue at -5.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Sutro Biopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about STRO's management, answered from reported figures.
Who manages STRO?
Sutro Biopharma, Inc. (STRO) lists 10 active executives. The top listed executive is Hans-Peter Gerber, Chief Scientific Officer.
Are STRO insiders buying or selling?
Recent insider activity shows net buying of $9.08M.
Continue the stock analysis
Jump to another research area for this company.